Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
Eric L. Simpson(Oregon Health & Science University), Ashish Bansal(Regeneron (United States)), Jamie Weisman(Institute for Advanced Medical Research), Amy S. Paller(Northwestern University), Emma Guttman‐Yassky(Icahn School of Medicine at Mount Sinai), Jennifer D. Hamilton(Regeneron (United States)), Thomas Hultsch(Sanofi (United States)), Laurent Eckert(Sanofi (France)), Mark Boguniewicz(University of Colorado Denver), David M. Pariser(Eastern Virginia Medical School), Bolanle Akinlade(Regeneron (United States)), Mohamed Kamal(Regeneron (United States)), Neil M.H. Graham(UK Dementia Research Institute), Andrew Blauvelt(Veterans Health Administration), Lisa A. Beck(Newcastle University), Neil Stahl(Arthritis and Rheumatism Associates), George D. Yancopoulos(Regeneron (United States)), Elaine C. Siegfried(Saint Louis University), Heribert Staudinger(Sanofi (United States)), Qin Zhang(Novartis (Switzerland)), Gianluca Pirozzi(Sanofi (United States)), Lawrence Sher(Peninsula Research), Abhijit Gadkari(Regeneron (United States)), Benjamin Lockshin(Georgetown University), John D. Davis(Providence College), Marcella Ruddy(Regeneron (United States)), Melinda Gooderham(Queen's University)
Cited by 505
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Regulation of the Germinal Center Response by MicroRNA-155
|Science|2007|1.5k